Literature DB >> 19962269

Enhancing exposure therapy for anxiety disorders with glucocorticoids: from basic mechanisms of emotional learning to clinical applications.

Dorothée Bentz1, Tanja Michael, Dominique J-F de Quervain, Frank H Wilhelm.   

Abstract

Current neurophysiological and psychological accounts view exposure therapy as the clinical analog of extinction learning that results in persistent modifications of the fear memory involved in the pathogenesis, symptomatology, and maintenance of anxiety disorders. Evidence from studies in animals and humans indicate that glucocorticoids have the potential to facilitate the processes that underlie extinction learning during exposure therapy. Particularly, glucocorticoids can restrict retrieval of previous aversive learning episodes and enhance consolidation of memory traces relating to non-fearful responding in feared situations. Thus, glucocorticoid treatment especially in combination with exposure therapy might be a promising approach to optimize treatment of anxiety disorders. This review examines the processes involved in aversive conditioning, fear learning and fear extinction, and how glucocorticoids might enhance restructuring of fear memories during therapy. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962269     DOI: 10.1016/j.janxdis.2009.10.011

Source DB:  PubMed          Journal:  J Anxiety Disord        ISSN: 0887-6185


  40 in total

1.  Extinction of conditioned fear is better learned and recalled in the morning than in the evening.

Authors:  Edward F Pace-Schott; Rebecca M C Spencer; Shilpa Vijayakumar; Nafis A K Ahmed; Patrick W Verga; Scott P Orr; Roger K Pitman; Mohammed R Milad
Journal:  J Psychiatr Res       Date:  2013-08-28       Impact factor: 4.791

Review 2.  Stress, glucocorticoids and memory: implications for treating fear-related disorders.

Authors:  Dominique de Quervain; Lars Schwabe; Benno Roozendaal
Journal:  Nat Rev Neurosci       Date:  2016-11-24       Impact factor: 34.870

Review 3.  Epigenetics and memory: causes, consequences and treatments for post-traumatic stress disorder and addiction.

Authors:  C L Pizzimenti; K M Lattal
Journal:  Genes Brain Behav       Date:  2015-01       Impact factor: 3.449

Review 4.  Stress and glucocorticoid receptor-dependent mechanisms in long-term memory: from adaptive responses to psychopathologies.

Authors:  Charles Finsterwald; Cristina M Alberini
Journal:  Neurobiol Learn Mem       Date:  2013-10-07       Impact factor: 2.877

Review 5.  Prospects for the pharmacological prevention of post-traumatic stress in vulnerable individuals.

Authors:  Sarah A Ostrowski; Douglas L Delahanty
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

6.  Glucocorticoids enhance extinction-based psychotherapy.

Authors:  Dominique J-F de Quervain; Dorothée Bentz; Tanja Michael; Olivia C Bolt; Brenda K Wiederhold; Jürgen Margraf; Frank H Wilhelm
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

7.  Cortisol awakening response in PTSD treatment: Predictor or mechanism of change.

Authors:  Sheila A M Rauch; Anthony King; H Myra Kim; Corey Powell; Nirmala Rajaram; Margaret Venners; Naomi M Simon; Mark Hamner; Israel Liberzon
Journal:  Psychoneuroendocrinology       Date:  2020-05-15       Impact factor: 4.905

Review 8.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.

Authors:  Michael L Sulkowski; Daniel A Geller; Adam B Lewin; Tanya K Murphy; Andrew Mittelman; Ashley Brown; Eric A Storch
Journal:  Curr Psychiatry Rev       Date:  2014

10.  Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

Authors:  Kate R Kuhlman; Michael Treanor; Gabriella Imbriano; Michelle G Craske
Journal:  Psychoneuroendocrinology       Date:  2020-03-20       Impact factor: 4.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.